## Phospho-CDC20 (Ser51) Antibody





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	<b>Reactivity:</b> H M	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 51	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #Q12834	Entrez-Gene Id: 991
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:50	
Storage		Supplied in 10 mM sod 20°C. Do not aliquot th		ö), 150 mM NaCl, 100 μg/	ml BSA and 50% gl	ycerol. Store at –
Specificity/Sen	sitivity	Phospho-CDC20 (Ser51 phosphorylated at Ser!		izes endogenous levels o	of CDC20 protein or	nly when
Species predict based on 100% homology		Rat				
Source / Purific	ation		Ser51 of human CI	munizing animals with a C20 protein. Antibodies		
Background		controlled by molecula Checkpoints monitor D G2/M transitions, respected it inactive. The tumor serestriction point (R) and Rb binds to and represe by CDKs induces Rb to vitro, Rb can be phosph both the G2/M and the phosphorylate Chk at Se phosphorylation at Ser CDC20 binds to and ac the cell cycle (12). More (APC/C). In metaphase is lost and CDC20-APC/ genotoxic stresses and cells leads to attenuate therapeutic target of c differentiation and sym neurons by triggering Phosphorylation of CD	r circuits called "ch DNA integrity and c ectively. The cdc2-c d at Thr14 and Tyr suppressor protein d is a major regula ses the transcripti dissociate from E2 horylated at multip e G1/S checkpoints Ser345 (9), Chk2 at tivates the anapha eover, CDC20 is ne MAD2L1 inactivate (C degrades its sub l ectopic introducti ed cell growth and ancer (14). Organiz apse formation. C the required degra C20 at Ser51 by C4 nhibited and trans	to avoid the accumulation neckpoints" that are com- ell growth prior to replice cyclin B kinase is pivotal 15 during G2-phase by the retinoblastoma (Rb) con- tor of the G1/S transition on factor E2F (5). The ph- F, permitting the transcription of actor E2F (5). The ph- F, permitting the transcription activation of cdc2. se-promoting complex ( cessary for ubiquitin ligates the CDC20-APC/C com- strates (13). p53 and p2 on of p53. siRNA mediates induces G(2)/M arrest, size tation of neuronal circuite DC20-APC regulates prese dation of the transcription MKIIβ disperses CDC20 ition from growth to retrive	mon to all eukaryod ation and division a in regulating the G2 ne kinases Wee1 an atrols progression the ophorylation of Rb iption of S-phase-p nd cdk4/6 (6-8). DN/ the DNA-PK/ATM/A The Chk kinases in APC) during mitosis se activity of the AP oplex, while in anap 1 suppress expressi ed knock-down of C uggesting that CDC is requires presynap synaptic differentiat on factor NeuroD2 from the centroson	tic cells (1). At the G1/S and 2/M transition (2,3). d Myt1, rendering prough the late G1 nd mid G1-phase, late in G1-phase romoting genes. <i>In</i> A damage triggers TR kinases, which activate cdc25 via and G1 phase of PC/cyclosome hase this inhibition on of CDC20 upon CDC20 in cancer 20 is a possible ptic axonal cion in postmitotic (15). ne. As a result,
Background Re	ferences	3. Watanabe, N. et al. ( 4. Sherr, C.J. (1996) <i>Scie</i> 5. Dyson, N. (1998) <i>Ger</i> 6. Kitagawa, M. et al. (1 7. Lundberg, A.S. and V 8. Harbour, J.W. et al. (1 9. Zhao, H. and Piwnica	se, P. (1992) Annu 1995) EMBO J 14, 1 ence 274, 1672-7. nes Dev 12, 2245-6 1996) EMBO J 15, 7 Neinberg, R.A. (199 999) Cell 98, 859-6 a-Worms, H. (2001) (2000) Proc Natl Ad	2. 060-9. 08) <i>Mol Cell Biol</i> 18, 753-( 9. <i>Mol Cell Biol</i> 21, 4129-3 <i>ad Sci USA</i> 97, 10389-94	51. 9.	

Fang, G. et al. (1998) *Mol Cell* 2, 163-71.
Fang, G. et al. (1998) *Genes Dev* 12, 1871-83.
Kidokoro, T. et al. (2008) *Oncogene* 27, 1562-71.
Yang, Y. et al. (2009) *Science* 326, 575-8.
Puram, S.V. et al. (2011) *Nat Neurosci*, .

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key	W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key	H: Human M: Mouse
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.